World J Gastroenterol 9(12):27762781
160,161 For example, HM15211, a triple agonist developed by Hanmi Pharmaceutical in South Korea that activates GLP-1R, GIPR and GCGR has entered early clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH)
Among emerging CKD-protective treatments, finerenone was approved by the FDA in 2021 and was also recommended in the 2022 KDIGO guidelines as first-line therapy for patients with type 2 diabetes who are at high risk of kidney disease progression and cardiovascular events [6, 15]
Drug-drug interactions and drug-age interactions were most common
Wegovy works systemically by entering the bloodstream and affecting appetite receptors in the brain
So for example, one pathway is called heat shock proteins